Elutia initiates EluPro clinical study to collect real-world outcome data

Elutia (ELUT) announced the initiation of an EluPro clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleared antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices and neurostimulators, was commercially launched earlier this year. The first patient was enrolled at UC San Diego Health. “Every innovation we pursue is driven by a commitment to improving patient care,” said Kimberly Mulligan, PhD, Vice President and General Manager of Cardiovascular at Elutia. “With EluPro, we combined trusted antibiotics with a soft, regenerative biomatrix to protect the implant, facilitate implantation, and support healing. This study will allow us to collect data on these differentiating characteristics in real-world practice.”